INS and type 2 diabetes mellitus: At the end of the COVID-19 pandemic, and to address the gap in the literature, our department conducted a cohort study aiming to compare the efficacy of CGM devices (FreeStyle Libre 2®; Abbott Laboratories, Chicago, IL, USA) versus CBG in glycemic control of inpatient type 2 diabetes on intensive insulin therapy [5].